Pipeline

Advancing Novel T Cell Engaging Immunotherapies

Harpoon is building a pipeline of wholly-owned immunotherapies harnessing the tumor-killing power of T cells for patients with difficult-to-treat tumors.

HPN424

PSMA TriTAC

Prostate Cancer
    

HPN536

MSLN TriTAC

Various Solid Tumors
    

HPN217

BCMA TriTAC

Multiple Myeloma
    

HPN823

DLL3 TriTAC

Small Cell Lung
Cancer
    

TriTAC

undisclosed targets

Various (oncology)
    

ProTriTAC

undisclosed targets

Various (oncology)
    
Product/Target
Indication